{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-003418","form_type":"8-K","ticker":"GNVR","cik":"0001792941","company_name":"Genvor Inc","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.553870+00:00","generated_at":"2026-06-06T20:09:28.135877+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Genvor appoints Chad Pawlak CEO, reshuffles executive team; Miller becomes CBO and Interim CFO","bullets":["Chad Pawlak appointed CEO with base salary of $300,000/year and up to 30% annual bonus tied to milestones.","Judith Miller resigns as Interim CEO, becomes CBO and Interim CFO with base salary of $180,000/year plus monthly stock grants.","Dr. Jesse Jaynes named Chief Scientific Officer; Dr. Clayton Yates resigns as CSO and becomes scientific advisor.","Executives receive milestone-based equity: Pawlak eligible for up to 4 million shares upon achieving product and regulatory goals.","Indemnification agreements entered into with all officers and directors effective January 17, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-003418","json":"https://secwatch.observer/filing/0001493152-24-003418.json","markdown":"https://secwatch.observer/filing/0001493152-24-003418.md","text":"https://secwatch.observer/filing/0001493152-24-003418.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792941/000149315224003418/0001493152-24-003418-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792941/000149315224003418/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:09:28.135877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04ca510edc","claim":"Judith S. Miller was appointed as member of the Board, Chief Business Officer, and Interim Chief Financial Officer at Genvor Inc.","evidence_excerpt":"Judith S. Miller resigned as the Company’s Interim Chief Executive Officer and was appointed as a member of the Company’s Board of Directors (the “ Board ”), as the Chief Business Officer of the Company, and as the Interim Chief Financial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792941/000149315224003418/0001493152-24-003418-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board, Chief Business Officer, and Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6ab23d92ab","claim":"Dr. Jesse Jaynes was appointed as Chief Scientific Officer at Genvor Inc.","evidence_excerpt":"Dr. Jesse Jaynes was appointed as the Chief Scientific Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792941/000149315224003418/0001493152-24-003418-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"9430920904","claim":"Dr. Clayton Yates was appointed as scientific advisor at Genvor Inc.","evidence_excerpt":"Dr. Clayton Yates resigned as Chief Scientific Officer of the Company and was appointed as a scientific advisor for the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792941/000149315224003418/0001493152-24-003418-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"scientific advisor"}],"fact_type":"executive_change"},{"claim_id":"b15ce34437","claim":"Chad Pawlak was appointed as Chief Executive Officer at Genvor Inc.","evidence_excerpt":"Chad Pawlak was appointed as Chief Executive Officer of Genvor Incorporated","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792941/000149315224003418/0001493152-24-003418-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}